Loading
An immune checkpoint on myeloid cells that works at the acidic pH inside tumours and is a suspected escape route after PD-1 therapy; antibodies are in early trials.
VISTA (VSIR, PD-1H) is expressed mainly on myeloid cells and naive T cells, binds PSGL-1 selectively at acidic pH (tumour microenvironment) and VSIG3, and suppresses T-cell activation. It is upregulated after anti-CTLA-4 in prostate cancer and after chemotherapy in some tumours, suggesting adaptive resistance. Anti-VISTA antibodies (CI-8993, SNS-101 which binds only at low pH, HMBD-002, KVA12123) are in phase 1/2; the first agent (JNJ-61610588) was halted for cytokine release. No efficacy has yet been shown.
In plain words · An immune checkpoint on myeloid cells that works at the acidic pH inside tumours and is a suspected escape route after PD-1 therapy; antibodies are in early trials.
An immune checkpoint on myeloid cells that works at the acidic pH inside tumours and is a suspected escape route after PD-1 therapy; antibodies are in early trials.
B7-family Ig-superfamily member acting as both ligand and receptor; histidine-rich extracellular domain makes PSGL-1 binding pH-dependent; expressed at high density on neutrophils, monocytes and MDSCs.
No product in this corpus aims at VISTA yet. Checkpoint drugs are antibodies that cover one side of an immune ‘stand down’ handshake so T cells stay active.
First described 2003. Earliest sequence paper UniProt cites for the protein: Sachs U.J. et al, 2003, "Gi24, a novel platelet receptor". Source.
B7-family Ig-superfamily member acting as both ligand and receptor; histidine-rich extracellular domain makes PSGL-1 binding pH-dependent; expressed at high density on neutrophils, monocytes and MDSCs.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Mesothelioma | 85% | IHC, any VISTA on tumour cells (TMA, n=319; 88% epithelioid, 90% biphasic, 42% sarcomatoid) | Expression on inflammatory cells in 94%; VISTA-high associated with better survival | doi.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Query for this target: (TITLE:"VISTA" OR ABSTRACT:"VISTA" OR TITLE:"VSIR" OR ABSTRACT:"VSIR") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about VISTA, not a curated reading list.
Shares Checkpoint (two meanings), PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-1, Immune checkpoint inhibitors.
Shares CTLA-4, PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-1, Pancreatic ductal adenocarcinoma.
Shares CTLA-4, Mesothelioma, PD-1, Immune checkpoint inhibitors.
Shares CTLA-4, PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-1, Immune checkpoint inhibitors.
Shares LAG-3, Checkpoint (two meanings), PD-1 / PD-L1 immune checkpoint & T-cell activation.
Shares Checkpoint (two meanings), CTLA-4, PD-1 / PD-L1 immune checkpoint & T-cell activation, Immune checkpoint inhibitors.
Shares Checkpoint (two meanings), CTLA-4, PD-1 / PD-L1 immune checkpoint & T-cell activation.